Next report date
Report period
Q2 2024
EPS estimate
—
Revenue estimate
1.12 BJPY
45JPY
923.14 MJPY
4.51 BJPY
9.24 M
About CELLSOURCE CO LTD
Sector
CEO
Takashi Sawada
Headquarters
Tokyo
Website
Employees (FY)
151
Founded
2015
ISIN
JP3423580004
FIGI
BBG00Q9X6X65
CellSource Co., Ltd. engages in regenerative medicine related business. Its business includes fat, blood-derived tissue and cell processing service. It also offers regenerative medicine legal support service, sale of medical device, cosmetics and facial products. It operates through the Regenerative Medicine-related and Consumer business segments. The Regenerative Medicine-related segment handles stem cell processing contract service, blood derived processing contract service and consulting service. It also sells equipment necessary for medical institutions to collect fat from patients. The Consumer segment mainly manufactures and sells cosmetics for the general consumer, such as beauty liquids, creams, facial cleansing gels, and own cosmetic brand SIGNALIFT. The company was founded on November 30, 2015 and is headquartered in Tokyo, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4880 is 1522 JPY — it has increased by 0.33% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange CELLSOURCE CO LTD stocks are traded under the ticker 4880.
CELLSOURCE CO LTD is going to release the next earnings report on Jun 10, 2024. Keep track of upcoming events with our Earnings Calendar.
4880 stock is 3.94% volatile and has beta coefficient of 0.35. Check out the list of the most volatile stocks — is CELLSOURCE CO LTD there?
CELLSOURCE CO LTD revenue for the last quarter amounts to 1.10 B JPY despite the estimated figure of 1.44 B JPY. In the next quarter revenue is expected to reach 1.22 B JPY.
Yes, you can track CELLSOURCE CO LTD financials in yearly and quarterly reports right on TradingView.
4880 stock has fallen by 0.72% compared to the previous week, the month change is a 3.12% rise, over the last year CELLSOURCE CO LTD has showed a 40.10% decrease.
4880 net income for the last quarter is 143.90 M JPY, while the quarter before that showed 248.00 M JPY of net income which accounts for −41.98% change. Track more CELLSOURCE CO LTD financial stats to get the full picture.
Today CELLSOURCE CO LTD has the market capitalization of 30.05 B, it has decreased by 1.49% over the last week.
Like other stocks, 4880 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELLSOURCE CO LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 151.00 employees. See our rating of the largest employees — is CELLSOURCE CO LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CELLSOURCE CO LTD technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CELLSOURCE CO LTD stock shows the sell signal. See more of CELLSOURCE CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CELLSOURCE CO LTD future price: according to them, 4880 price has a max estimate of 1800.00 JPY and a min estimate of 1800.00 JPY. Read a more detailed CELLSOURCE CO LTD forecast: see what analysts think of CELLSOURCE CO LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELLSOURCE CO LTD EBITDA is 1.15 B JPY, and current EBITDA margin is 28.55%. See more stats in CELLSOURCE CO LTD financial statements.